Core Viewpoint - MicroPort Medical (00853) has seen a stock increase of over 4%, currently trading at HKD 12.27 with a transaction volume of HKD 79.53 million, following the approval of a merger agreement by independent shareholders of MicroPort Cardiac at a special meeting scheduled for December 15, 2025 [1] Group 1: Merger and Strategic Moves - The merger is expected to be completed around December 19, 2025, and is a key initiative for optimizing resource allocation and enhancing overall competitiveness in the structural heart disease and rhythm management sectors [1] - The strategic merger aims to strengthen the synergy between both companies in their respective fields [1] Group 2: Financial Performance and Projections - Citigroup noted that MicroPort Medical's fundamentals are continuously improving, with a 66% year-on-year reduction in net losses for the first half of 2025, and anticipates profitability in the second half of 2025 [1] - The overseas platform is projected to achieve a year-on-year growth of 70% to 80% in 2025, with a continued growth trend expected into 2026 [1] - Everbright Securities has raised its net profit forecasts for 2025 and 2026 to -30 million and -96 million USD respectively, from previous estimates of -59 million and -91 million USD, considering factors such as the impact of centralized procurement and cost reductions [1]
微创医疗涨超4% 花旗料公司25年下半年将录得盈利 此前战略合并将成为上行潜力